Meropenem Kabi

Meropenem, the active ingredient in Meropenem Kabi, is a carbapenem presented as an injectable solution for intravenous use. It is employed to treat severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, hospital‑acquired and ventilator‑associated pneumonia, meningitis, and septic shock in hospitalized patients, including critically ill patients.

GNH USA supplies Meropenem Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, clinics and health‑care institutions worldwide. All batches are manufactured under EU GMP standards and undergo rigorous quality testing before release.

Meropenem is a broad‑spectrum carbapenem antibiotic used to treat serious infections caused by susceptible bacteria. - Complicated intra‑abdominal infections: provides rapid bactericidal activity to eradicate pathogens and resolve infection. - Complicated urinary tract infections: eliminates causative organisms and helps restore urinary tract sterility. - Hospital‑acquired pneumonia: targets resistant Gram‑negative and Gram‑positive bacteria to improve pulmonary outcomes. - Ventilator‑associated pneumonia: delivers high tissue concentrations to treat ventilator‑related lung infections. - Meningitis: penetrates the cerebrospinal fluid to achieve therapeutic levels against meningitic pathogens. - Severe sepsis and septic shock: offers broad coverage to control systemic infection and support hemodynamic recovery.

Adverse reactions to Meropenem may vary in frequency and severity.

Common Side Effects: - Nausea: mild gastrointestinal upset reported in many patients. - Diarrhea: loose stools, occasionally leading to dehydration. - Rash: skin erythema or pruritus without systemic involvement. - Infusion site reactions: erythema, pain or phlebitis at the injection site. - Elevated liver enzymes: transient increases in ALT or AST. - Headache: mild to moderate head discomfort.

Serious or Rare Side Effects: - Seizures: especially in patients with renal impairment or pre‑existing CNS disorders. - Clostridioides difficile‑associated diarrhea: severe colitis requiring specific therapy. - Anaphylaxis: acute, life‑threatening hypersensitivity reaction. - Severe allergic reactions: including Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Renal toxicity: acute kidney injury in susceptible individuals. - Thrombocytopenia: marked reduction in platelet count.

Before initiating Meropenem therapy, clinicians should consider several safety precautions. - Assess renal function: dose adjustment may be required in patients with impaired clearance. - Monitor for seizures: risk increases in renal failure, CNS disease or high‑dose therapy. - Review allergy history: avoid use in patients with known hypersensitivity to β‑lactams. - Adjust for hepatic impairment: consider reduced dosing in severe liver disease. - Use cautiously in neonates and infants: limited data require careful monitoring. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Valproic acid: carbapenems markedly reduce serum valproate concentrations, risking seizure breakthrough. - Concurrent carbapenem therapy: additive toxicity and no clinical benefit from overlapping agents. - High‑dose aminoglycosides: increased risk of nephrotoxicity when combined with Meropenem.

Moderate Interactions (Monitor Closely): - Loop diuretics: may exacerbate renal dysfunction; monitor kidney function and electrolytes. - NSAIDs: potential additive renal impairment; assess renal status regularly. - Warfarin: carbapenems may enhance anticoagulant effect; check INR more frequently. - Phenytoin: possible alteration of plasma levels; monitor seizure control.